Amantadine and rimantadine for preventing and treating influenza A in adults
- 19 July 2004
- reference entry
- Published by Wiley
- No. 3,p. CD001169
- https://doi.org/10.1002/14651858.cd001169.pub2
Abstract
Amantadine hydrochloride and rimantadine hydrochloride have antiviral properties, but these drugs are not widely used due to a lack of knowledge of their potential value and concerns about possible adverse effects. The objective of this review was to assess the effectiveness and safety ("effects") of amantadine and rimantadine in healthy adults. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 4, 2003), MEDLINE (January 1966 to November week 2, 2003), EMBASE (January 1990 to September 2003) and the reference lists of articles. We also contacted manufacturers, researchers and authors. Randomised and quasi‐randomised studies comparing amantadine and/or rimantadine with placebo, control antivirals or no intervention, or comparing doses or schedules of amantadine and/or rimantadine in healthy adults. For prevention trials the numbers of participants with clinical influenza (influenza‐like‐illness or ILI), i.e. confirmed influenza A, and adverse effects were analysed. Analysis for treatment trials included the mean duration of fever and length of hospital stay, and the number of adverse effects. Amantadine prevented 25% of ILI cases (95% confidence interval (CI) 13% to 36%), and 61% of influenza A cases (95% CI 35% to 76%). Amantadine reduced duration of fever by one day (95% CI 0.7 to 1.3). Rimantadine demonstrated comparable effectiveness, but there were fewer trials and the results for prevention were not statistically significant. Both amantadine and rimantadine induced significant gastrointestinal adverse effects. Adverse effects of the central nervous system and study withdrawals were significantly more common with amantadine than rimantadine. Amantadine and rimantadine have comparable effectiveness in the prevention and treatment of influenza A in healthy adults, although rimantadine causes fewer adverse effects than amantadine. [This abstract was prepared centrally.]Keywords
This publication has 48 references indexed in Scilit:
- Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemicAntimicrobial Agents and Chemotherapy, 1990
- Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adultsAntimicrobial Agents and Chemotherapy, 1986
- INFLUENZA A PROPHYLAXIS WITH AMANTADINE IN A BOARDING SCHOOLThe Lancet, 1984
- A Controlled Trial of Amantadine and Rimantadine in the Prophylaxis of Influenza a InfectionNew England Journal of Medicine, 1982
- Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramineAntimicrobial Agents and Chemotherapy, 1982
- Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adultsAntimicrobial Agents and Chemotherapy, 1981
- Therapeutic Effects of Aerosolized Amantadine in Naturally Acquired Infection Due to Influenza A VirusThe Journal of Infectious Diseases, 1980
- THERAPEUTIC EFFECT OF 1-ADAMANTANAMINE HYDROCHLORIDE IN NATURALLY OCCURRING INFLUENZA A2/HONG KONG INFECTION: A Controlled Double-blind StudyPublished by Elsevier ,1971
- Protection of Man from Natural Infection with Influenza A2 Hong Kong Virus by Amantadine: A Controlled Field TrialBMJ, 1970
- Amantadine Therapy of Epidemic Influenza A 2 (Hong Kong)Infection and Immunity, 1970